These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23514751)

  • 21. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics.
    Liu Y; Xie QR; Wang B; Shao J; Zhang T; Liu T; Huang G; Xia W
    Protein Cell; 2013 Sep; 4(9):702-10. PubMed ID: 23982738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
    Kim JH; Lee JO; Kim N; Lee HJ; Lee YW; Kim HI; Kim SJ; Park SH; Kim HS
    Int J Oncol; 2015 Nov; 47(5):1874-80. PubMed ID: 26397839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer.
    Zhao J; Zhang H; Lei T; Liu J; Zhang S; Wu N; Sun B; Wang M
    Cancer Biol Med; 2020 Nov; 17(4):1014-1025. PubMed ID: 33299650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT6, a novel direct transcriptional target of FoxO3a, mediates colon cancer therapy.
    Zhang Y; Nie L; Xu K; Fu Y; Zhong J; Gu K; Zhang L
    Theranostics; 2019; 9(8):2380-2394. PubMed ID: 31149050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.
    Chi Y; Xue J; Huang S; Xiu B; Su Y; Wang W; Guo R; Wang L; Li L; Shao Z; Jin W; Wu Z; Wu J
    Theranostics; 2019; 9(23):6840-6855. PubMed ID: 31660072
    [No Abstract]   [Full Text] [Related]  

  • 26. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
    Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
    J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.
    Boreddy SR; Pramanik KC; Srivastava SK
    Clin Cancer Res; 2011 Apr; 17(7):1784-95. PubMed ID: 21350002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3α-dependent antioxidant defense mechanisms.
    Wang XX; Wang XL; Tong MM; Gan L; Chen H; Wu SS; Chen JX; Li RL; Wu Y; Zhang HY; Zhu Y; Li YX; He JH; Wang M; Jiang W
    Basic Res Cardiol; 2016 Mar; 111(2):13. PubMed ID: 26786260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer.
    Azuma Y; Yokobori T; Mogi A; Altan B; Yajima T; Kosaka T; Onozato R; Yamaki E; Asao T; Nishiyama M; Kuwano H
    J Surg Oncol; 2015 Aug; 112(2):231-7. PubMed ID: 26180037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
    Zhu D; Zha X; Hu M; Tao A; Zhou H; Zhou X; Sun Y
    Med Oncol; 2012 Dec; 29(5):3207-15. PubMed ID: 22544540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair.
    McCord RA; Michishita E; Hong T; Berber E; Boxer LD; Kusumoto R; Guan S; Shi X; Gozani O; Burlingame AL; Bohr VA; Chua KF
    Aging (Albany NY); 2009 Jan; 1(1):109-21. PubMed ID: 20157594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel nuclear localization region in SIPA1 determines protein nuclear distribution and epirubicin-sensitivity of breast cancer cells.
    Ma Y; Weng J; Wang N; Zhang Y; Minato N; Su L
    Int J Biol Macromol; 2021 Jun; 180():718-728. PubMed ID: 33753200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
    Flamant L; Roegiers E; Pierre M; Hayez A; Sterpin C; De Backer O; Arnould T; Poumay Y; Michiels C
    BMC Cancer; 2012 Sep; 12():391. PubMed ID: 22954140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
    Cagnetta A; Soncini D; Orecchioni S; Talarico G; Minetto P; Guolo F; Retali V; Colombo N; Carminati E; Clavio M; Miglino M; Bergamaschi M; Nahimana A; Duchosal M; Todoerti K; Neri A; Passalacqua M; Bruzzone S; Nencioni A; Bertolini F; Gobbi M; Lemoli RM; Cea M
    Haematologica; 2018 Jan; 103(1):80-90. PubMed ID: 29025907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.
    Han CY; Cho KB; Choi HS; Han HK; Kang KW
    Carcinogenesis; 2008 Sep; 29(9):1837-44. PubMed ID: 18390843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12.
    Sun WL; Wang L; Luo J; Zhu HW; Cai ZW
    Cancer Sci; 2018 Oct; 109(10):3129-3138. PubMed ID: 30027574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.
    Xiang S; Dauchy RT; Hoffman AE; Pointer D; Frasch T; Blask DE; Hill SM
    J Pineal Res; 2019 Sep; 67(2):e12586. PubMed ID: 31077613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXO3a‑SIRT6 axis suppresses aerobic glycolysis in melanoma.
    Dong Z; Yang J; Li L; Tan L; Shi P; Zhang J; Zhong X; Ge L; Wu Z; Cui H
    Int J Oncol; 2020 Mar; 56(3):728-742. PubMed ID: 32124950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.